Maxcyte
MXCT on Nasdaq. Maxcyte sells technology for engineering cells to biopharmaceutical companies. Market value $123m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-18.18 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 20 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$1.26 a share, 96% above its 1-year low
Over the past year the price has ranged from $0.64 to $1.80.
Pays no dividend
Price from Friday’s close (6 November).
Five years of cash, in billions
Spare cash swings from quarter to quarter here: a shortfall of $24 million in the past 12 months, a shortfall of $36 million in the year to December 2025.
| Revenue | |||||
| Revenue | $34m | $44m | $41m | $39m | $33m |
| Operating margin | |||||
| Operating margin | -53.7% | -61.8% | -117.0% | -132.5% | -157.1% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.10bn | 0.10bn | 0.11bn | 0.11bn | 0.10bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsShrinking, 0.6% a year
- Buying back its own sharesRoughly flat
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $7 million last quarter, down 15% on a year ago.
- A loss of $9 million, compared with a loss of $12 million a year ago.
- It loses 135 cents on each $1 of sales, compared with 150 cents a year earlier.
- Over the past 12 months it spent $24 million more cash than it brought in, compared with $38 million a year earlier.
- About the same number of shares as a year ago.
- Sales did not grow on a year ago in any of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $8m |
| December 2024 | $9m |
| March 2025 | $10m |
| June 2025 | $9m |
| September 2025 | $7m |
| December 2025 | $7m |
| March 2026 | $10m |
| June 2026 | $7m |
| Quarter to | Amount |
|---|---|
| September 2024 | -$12m |
| December 2024 | -$11m |
| March 2025 | -$10m |
| June 2025 | -$12m |
| September 2025 | -$12m |
| December 2025 | -$10m |
| March 2026 | -$5m |
| June 2026 | -$9m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 25 March 2026
- Next quarterly (estimated, 10-Q)
- 9 February 2027
Who owns it
None of the long-term investors we follow own it. 123 funds in all.
Largest holders overall
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
2 investors own more than 5%.
- Capricorn Fund Managers LtdPassive investor7.7%Since 30 January 2026
- Cadian Capital Management, LPPassive investorat least 3.5%−4.2 pts(filed with 2 related holders)Since 31 December 2025
- Liontrust Investment Partners LLPPassive investorSold down below 5%Since 30 October 2026
What they said
(a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer
Read the filing - BlackRock, Inc.Passive investorSold down below 5%Since 30 June 2026
- RIVER GLOBAL INVESTORS LLPSold down below 5%Since 31 July 2026
What they said
(b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries. As per the Announcement on 24 June 2026 (RNS Number: 4421J), the FCA has approved the change in control and proposed acquisition of River…
Read the filing - Mirabella Financial Services LLPPassive investorSold down below 5%Since 31 March 2026
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Capricorn Fund Managers Ltd Passive investor | 7.7% | 30 January 2026 | |
Cadian Capital Management, LP Passive investor | at least 3.5%−4.2 pts (filed with 2 related holders) | 31 December 2025 | |
Liontrust Investment Partners LLP Passive investor | Sold down below 5% | 30 October 2026 | What they said(a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer Read the filing |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 June 2026 | |
RIVER GLOBAL INVESTORS LLP | Sold down below 5% | 31 July 2026 | What they said(b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries. As per the Announcement on 24 June 2026 (RNS Number: 4421J), the FCA has approved the change in control and proposed acquisition of River… Read the filing |
Mirabella Financial Services LLP Passive investor | Sold down below 5% | 31 March 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $120,780 of shares on the open market. 1 sold $8,316.
- Masoud MaherPresident and CEO, DirectorBought
- Date
- 17 November 2026
- Shares
- 100,000
- Price
- $1.21
- Value
- $120,780
- Swirsky Douglas JCHIEF FINANCIAL OFFICERSold
- Date
- 17 March 2026
- Shares
- 10,142
- Price
- $0.82
- Value
- $8,316
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 17 November 2026 | Masoud Maher President and CEO, Director | Bought | 100,000 | $1.21 | $120,780 |
| 17 March 2026 | Swirsky Douglas J CHIEF FINANCIAL OFFICER | Sold | 10,142 | $0.82 | $8,316 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the serious warning signs we check for were found. 1 thing worth knowing.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 25 Mar 2026, plus the 10-Q filed 10 Nov 2026 and 7 later 8-Ks.
One big customer
Worth knowingOne customer brings in a big share of sales: 26% last year. Losing that customer would hurt.
“During the years ended December 31, 2025 and 2024, one customer represented 26% and 23% of revenue, respectively.”
From the 10-K filed 25 March 2026, Item 8. Financial Statements and Notes. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- Sales have shrunk: 0.6% a year.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.